We demonstrate the feasibility of preclinical testing in mouse sarcoma cell lines and immunocompetent sarcoma SAMs using NTRK inhibitor treatment in ETV6::NTRK3-driven sarcomas. This evidence concerns the gene NTRK3 and sarcoma.